Prescription Drug Education - Opioid Abuse
Preventing abuse of prescription medicines

Prescription Drug Education Program

Education for Prevention

The member companies of the Association for Accessible Medicines are committed to preventing the misuse of prescription drugs and opioid abuse.

According to the Centers for Disease Control and Prevention, opioid abuse is now the No. 1 cause of accidental deaths in the U.S. College campuses, which historically are places for experimentation and risky behavior, are undergoing a spike in abuse. A recent study finds that about one in five college students knows someone who is addicted to pain medications, and nearly a third know someone who overdosed on painkillers or heroin.

In response to this crisis, last year AAM launched the Prescription Drug Safety Network, an evidence-based curriculum last year to help prevent abuse on campus—and it’s free to any college in America. Created with EVERFI, a leader in digital learning and prevention education solutions, the curriculum equips students with the knowledge and skills they need to help make healthy choices. The program builds on EVERFI’s groundbreaking AlcoholEdu, which is used on more than 500 campuses and by 36 percent of all first-year students at America’s four-year institutions of higher education. AlcoholEdu is the only program proven to reduce negative alcohol-related consequences among students.

This innovative digital learning course uses an evidence-based approach to encourage safe and responsible decision-making. It is available at no cost to incoming college freshmen through EverFi’s Campus Prevention Network.

Bring the Prescription Drug Safety Network to a college in your state.

If you are interested in having your college or university take part of this fully funded prescription drug education program, sign up your school now!

Download Brochure

Press Release

On the Blog


Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.